Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4

被引:9
作者
Shaker, Olfat [1 ,2 ]
El-Shehaby, Amal [1 ,2 ]
Fayez, Salwa [1 ,2 ]
Zahra, Amr [3 ]
Marzouk, Samar [1 ,2 ]
El Raziky, Maissa [4 ]
机构
[1] Cairo Univ, Fac Med, Dept Med Biochem, Cairo, Egypt
[2] Cairo Univ, Fac Med, Dept Mol Biol, Cairo, Egypt
[3] Fayoom Univ, Fayoom, Egypt
[4] Cairo Univ, Fac Med, Endem Med & Hepatol Dept, Cairo, Egypt
关键词
hepatitis C; osteopontin; polymorphism; PEGINTERFERON PLUS RIBAVIRIN; VIRUS GENOTYPE; VIROLOGICAL RESPONSE; MACROPHAGE-MIGRATION; PROMOTER REGION; KUPFFER CELLS; EXPRESSION; RESISTANCE; ALPHA-2A; LIVER;
D O I
10.1002/cbf.2954
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to determine the relationship between osteopontin gene polymorphisms and its protein level and the efficacy of interferon-based therapies in Hepatitis C virus (HCV) patients. Hundreds HCV patients genotype 4, treated with pegylated interferon alfa-2b plus ribavirin and 60 healthy subjects were enrolled. All individuals were subjected to clinical and laboratory parameters, including hepatitis markers and HCV quantitation by real-time polymerase chain reaction. Single nucleotide polymorphisms (SNPs) of osteopontin (OPN) gene (nucleotide -155, -443 and -1748) were analysed by direct sequencing in addition to estimation of serum level of OPN. SNP at -443 (C/C versus C/T, T/T) was found to represent predictors for treatment response by univariate logistic regression analysis. OPN serum level was independent predictors for treatment response by both univariate and multivariate logistic regression analysis. SNP at nucleotide -443 and serum OPN protein levels could be used as useful markers to predict the efficacy of treatment. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:620 / 625
页数:6
相关论文
共 30 条
  • [1] Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Akuta, Norio
    Suzuki, Fumitaka
    Kawamura, SuzukiYusuke
    Yatsuji, Hiromi
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (11) : 1686 - 1695
  • [2] Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy
    Akuta, Norio
    Suzuki, Fumitaka
    Hirakawa, Miharu
    Kawamura, Yusuke
    Yatsuji, Hiromi
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    [J]. INTERVIROLOGY, 2009, 52 (06) : 301 - 309
  • [3] Correlation between virus genotype and chronicity rate in acute hepatitis C
    Amoroso, P
    Rapicetta, M
    Tosti, ME
    Mele, A
    Spada, E
    Buonocore, S
    Lettieri, G
    Pierri, P
    Chionne, P
    Ciccaglione, AR
    Sagliocca, L
    [J]. JOURNAL OF HEPATOLOGY, 1998, 28 (06) : 939 - 944
  • [4] Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
    Ashkar, S
    Weber, GF
    Panoutsakopoulou, V
    Sanchirico, ME
    Jansson, M
    Zawaideh, S
    Rittling, SR
    Denhardt, DT
    Glimcher, MJ
    Cantor, H
    [J]. SCIENCE, 2000, 287 (5454) : 860 - 864
  • [5] BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1002/hep.1840210306
  • [6] High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
    Bressler, BL
    Guindi, M
    Tomlinson, G
    Heathcote, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 639 - 644
  • [7] Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
    Cerny, A
    Chisari, FV
    [J]. HEPATOLOGY, 1999, 30 (03) : 595 - 601
  • [8] Gene modulation for treating liver fibrosis
    Cheng, Kun
    Mahato, Ram I.
    [J]. CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2007, 24 (02): : 93 - 146
  • [9] Response to Pegylated Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4
    El Makhzangy, Hesham
    Esmat, Gamal
    Said, Mohamed
    ElRaziky, Maissa
    Shouman, Soheir
    Refai, Rasha
    Rekacewicz, Claire
    Gad, Rita Raafat
    Vignier, Nicolas
    Abdel-Hamid, Mohamed
    Zalata, Khaled
    Bedossa, Pierre
    Pol, Stanislas
    Fontanet, Arnaud
    Mohamed, Mostafa K.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (09) : 1576 - 1583
  • [10] HALFON P, 2010, J HEPATOL, V52, P319